As of 2026-01-08, the EV/EBITDA ratio of Chinook Therapeutics Inc (KDNY) is -11.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KDNY's latest enterprise value is 2,773.05 mil USD. KDNY's TTM EBITDA according to its financial statements is -233.23 mil USD. Dividing these 2 quantities gives us the above KDNY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 15.2x | 14.9x |
| Forward P/E multiples | 19.8x - 34.6x | 22.0x |
| Fair Price | (62.41) - (47.54) | (58.16) |
| Upside | -254.5% - -217.7% | -244.0% |
| Date | EV/EBITDA |